Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115195) titled 'Evaluation of the Effect and Strategy Optimization of the New Individualized Diagnosis and Treatment Plan for Type 2 Diabetes: A National Multi-center Real-world Study: The efficacy and safety of Hengpagliflozin in Different Diabetes Subtypes' on Dec. 23, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Beijing Hospital
Condition:
diabetes
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2025-12-25
Target Sample Size: Observation group:3000;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=277614
P...